184 related articles for article (PubMed ID: 38560563)
1. Development of a cell adhesion-based prognostic model for multiple myeloma: Insights into chemotherapy response and potential reversal of adhesion effects.
Hu Q; Wang M; Wang J; Tao Y; Niu T
Oncol Res; 2024; 32(4):753-768. PubMed ID: 38560563
[TBL] [Abstract][Full Text] [Related]
2. ADP-ribosylation factor 1 (ARF1) takes part in cell proliferation and cell adhesion-mediated drug resistance (CAM-DR).
Xu X; Wang Q; He Y; Ding L; Zhong F; Ou Y; Shen Y; Liu H; He S
Ann Hematol; 2017 May; 96(5):847-858. PubMed ID: 28238095
[TBL] [Abstract][Full Text] [Related]
3. Elucidating the expression and function of Numbl during cell adhesion-mediated drug resistance (CAM-DR) in multiple myeloma (MM).
Huang Y; Huang X; Cheng C; Xu X; Liu H; Yang X; Yao L; Ding Z; Tang J; He S; Wang Y
BMC Cancer; 2019 Dec; 19(1):1269. PubMed ID: 31888545
[TBL] [Abstract][Full Text] [Related]
4. Role of Myeloma-Derived MIF in Myeloma Cell Adhesion to Bone Marrow and Chemotherapy Response.
Zheng Y; Wang Q; Li T; Qian J; Lu Y; Li Y; Bi E; Reu F; Qin Y; Drazba J; Hsi E; Yang J; Cai Z; Yi Q
J Natl Cancer Inst; 2016 Nov; 108(11):. PubMed ID: 27381622
[TBL] [Abstract][Full Text] [Related]
5. Wnt3/RhoA/ROCK signaling pathway is involved in adhesion-mediated drug resistance of multiple myeloma in an autocrine mechanism.
Kobune M; Chiba H; Kato J; Kato K; Nakamura K; Kawano Y; Takada K; Takimoto R; Takayama T; Hamada H; Niitsu Y
Mol Cancer Ther; 2007 Jun; 6(6):1774-84. PubMed ID: 17575106
[TBL] [Abstract][Full Text] [Related]
6. Effects of DTX3L on the cell proliferation, adhesion, and drug resistance of multiple myeloma cells.
Shen Y; Sun Y; Zhang L; Liu H
Tumour Biol; 2017 Jun; 39(6):1010428317703941. PubMed ID: 28653881
[TBL] [Abstract][Full Text] [Related]
7. Expression of vaccinia-related kinase 1 (VRK1) accelerates cell proliferation but overcomes cell adhesion mediated drug resistance (CAM-DR) in multiple myeloma.
Liu J; Wang Y; He S; Xu X; Huang Y; Tang J; Wu Y; Miao X; He Y; Wang Q; Liang L; Cheng C
Hematology; 2016 Dec; 21(10):603-612. PubMed ID: 27319807
[TBL] [Abstract][Full Text] [Related]
8. Cell adhesion mediated drug resistance (CAM-DR): role of integrins and resistance to apoptosis in human myeloma cell lines.
Damiano JS; Cress AE; Hazlehurst LA; Shtil AA; Dalton WS
Blood; 1999 Mar; 93(5):1658-67. PubMed ID: 10029595
[TBL] [Abstract][Full Text] [Related]
9. The PI3K/AKT signaling pathway regulates ABCG2 expression and confers resistance to chemotherapy in human multiple myeloma.
Wang L; Lin N; Li Y
Oncol Rep; 2019 Mar; 41(3):1678-1690. PubMed ID: 30664164
[TBL] [Abstract][Full Text] [Related]
10. EphA4 promotes cell proliferation and cell adhesion-mediated drug resistance via the AKT pathway in multiple myeloma.
Ding L; Shen Y; Ni J; Ou Y; Ou Y; Liu H
Tumour Biol; 2017 Mar; 39(3):1010428317694298. PubMed ID: 28351297
[TBL] [Abstract][Full Text] [Related]
11. Cell adhesion to fibronectin down-regulates the expression of Spy1 and contributes to drug resistance in multiple myeloma cells.
Fei M; Hang Q; Hou S; Ruan C
Int J Hematol; 2013 Oct; 98(4):446-55. PubMed ID: 24037419
[TBL] [Abstract][Full Text] [Related]
12. Pyruvate kinase isoform M2 (PKM2) participates in multiple myeloma cell proliferation, adhesion and chemoresistance.
He Y; Wang Y; Liu H; Xu X; He S; Tang J; Huang Y; Miao X; Wu Y; Wang Q; Cheng C
Leuk Res; 2015 Dec; 39(12):1428-36. PubMed ID: 26453405
[TBL] [Abstract][Full Text] [Related]
13. RBQ3 participates in multiple myeloma cell proliferation, adhesion and chemoresistance.
Liu H; Ding L; Shen Y; Zhong F; Wang Q; Xu X
Int J Biol Macromol; 2016 Oct; 91():115-22. PubMed ID: 27189701
[TBL] [Abstract][Full Text] [Related]
14. The role of ubiquitin-specific protease 14 (USP14) in cell adhesion-mediated drug resistance (CAM-DR) of multiple myeloma cells.
Xu X; Liu J; Shen C; Ding L; Zhong F; Ouyang Y; Wang Y; He S
Eur J Haematol; 2017 Jan; 98(1):4-12. PubMed ID: 26710889
[TBL] [Abstract][Full Text] [Related]
15. Epigenetic mechanisms of cell adhesion-mediated drug resistance in multiple myeloma.
Furukawa Y; Kikuchi J
Int J Hematol; 2016 Sep; 104(3):281-92. PubMed ID: 27411688
[TBL] [Abstract][Full Text] [Related]
16. Bortezomib overcomes cell-adhesion-mediated drug resistance through downregulation of VLA-4 expression in multiple myeloma.
Noborio-Hatano K; Kikuchi J; Takatoku M; Shimizu R; Wada T; Ueda M; Nobuyoshi M; Oh I; Sato K; Suzuki T; Ozaki K; Mori M; Nagai T; Muroi K; Kano Y; Furukawa Y; Ozawa K
Oncogene; 2009 Jan; 28(2):231-42. PubMed ID: 18850009
[TBL] [Abstract][Full Text] [Related]
17. Protein Kinase D 1 Predicts Poor Treatment Response and Unfavorable Survival of Bortezomib-Based Treatment, and Its Knockdown Enhances Drug Sensitivity to Bortezomib in Multiple Myeloma.
Li X; Yang Y; Yi X
Technol Cancer Res Treat; 2020; 19():1533033820936770. PubMed ID: 32799769
[TBL] [Abstract][Full Text] [Related]
18. miR-215-5p is an anticancer gene in multiple myeloma by targeting RUNX1 and deactivating the PI3K/AKT/mTOR pathway.
Liu S; Zhang Y; Huang C; Lin S
J Cell Biochem; 2020 Feb; 121(2):1475-1490. PubMed ID: 31498483
[TBL] [Abstract][Full Text] [Related]
19. Cell adhesion downregulates the expression of Homer1b/c and contributes to drug resistance in multiple myeloma cells.
Tang J; Zhou H; Wang C; Fei X; Zhu L; Huang Y; He Y; Liu J; Miao X; Wu Y; Wang Y
Oncol Rep; 2016 Mar; 35(3):1875-83. PubMed ID: 26718835
[TBL] [Abstract][Full Text] [Related]
20. Blockade of SDF-1/CXCR4 reduces adhesion-mediated chemoresistance of multiple myeloma cells via interacting with interleukin-6.
Liu Y; Liang HM; Lv YQ; Tang SM; Cheng P
J Cell Physiol; 2019 Nov; 234(11):19702-19714. PubMed ID: 30953364
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
